Does the antimigraine action of flunarizine involve the dopaminergic system? A clinical-neuroendocrinological study

Cephalalgia

Volumn 19, Issue 1, 1999, Pages 27-31

  Cupini, L M ^a   Troisi, E ^c   Placidi, F ^a   Diomedi, M ^a   Silvestrini, M ^a   Argiro, G ^b   Bernardi, G ^a,c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b S EUGENIO HOSPITAL   (Italy)

^c IRCCSS   (Italy)

Author keywords

Bromocriptine; Flunarizine; Migrainous

Indexed keywords

FLUNARIZINE; FOLLITROPIN; GROWTH HORMONE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HUMAN; MIGRAINE;

ADULT; ANALYSIS OF VARIANCE; BROMOCRIPTINE; CALCIUM CHANNEL BLOCKERS; DOPAMINE AGONISTS; FEMALE; FLUNARIZINE; HUMANS; MIGRAINE DISORDERS; NEUROSECRETORY SYSTEMS; PROLACTIN; RECEPTORS, DOPAMINE; TREATMENT OUTCOME;

EID: 0033017912     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-2982.1999.1901027.x     Document Type: Article

References (34)

1. Montastruc JL, Senard JM. Calcium channel blockers and prevention of migraine. Pathol Biol (Paris) 1992;40:381-8
2. Fisher M, Grotta J. New uses for calcium channel blockers. Therapeutic implications. Drugs 1993;46:961-75
3. Peroutka SJ. The pharmacology of current anti-migraine drugs. Headache 1990:5-11
4. Brucke T, Wöber CH, Podreka I, Wöber Bingöl C, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab 1995;15:513-8
5. Mena MA, Garcia de Yebenes JM, Tabernero C, Casarejos MJ, Pardo B, Yebenes JG. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995;5:410-26
6. Veitch K, Hue Louis. Flunarizine and cinnarizine inhibit mitochondrial complexes I and II. Possible implication for Parkinsonism. Mol Pharmacol 1993;45:158-63
7. Chouza C, Caamano JL, Aljanati R, Scaramelli A, De Medina O, Romero S. Parkinsonism, tardive dyskinesia, akathisia and depression induced by flunarizine. Lancet 1986:1303-4
8. Lugaresi A, Montagna P, Gallassi R, Lugaresi E. Extrapyramidal syndrome and depression induced by flunarizine. Eur Neurol 1988;28:208-11
9. Louis P. A double-blind placebo-controlled prophylactic study of flunarizine (sibelium) in migraine. Headache 1981:235-9
10. Rascol A, Montastruc JL, Rasco O. Flunarizine versus pizotifen: A double-blind study in the prophylaxis of migraine. Headache 1986;26:83-5
11. Sorensen PS, Hansen K, Olesen J. A placebo controlled, double-blind, cross-over trial of flunarizine in common migraine. Cephalalgia 1986;6:7-14
12. Gawel MJ, Kreeft J, Simard D, Nelson R. Comparison of the efficacy and safety of flunarizine and propanolol in the prophylaxis of migraine. Can J Neurol Sci 1992;19:340-5
13. Ambrosio C, Stefanini E. Interaction of flunarizine with dopamine D2 and D1 receptors. Eur J Pharmacol 1991;197:221-3
14. Wöber C, Brucke T, Wöber-Bingöl C, Asenbaum S, Wessely P, Podreka I. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia 1994:235-40
15. Diana M, Pani L, Rossetti Z, et al. Flunarizine attenuates cocaine-induced inhibition of A9 dopaminergic neurons. Pharmacol Res 1991;24:197-203
16. Devoto P, Pani L, Kuzmin A, De Montis G. Inhibition of [3H]dopamine uptake by flunarizine. Eur J Pharmacol 1991 ;203:67-9
17. Piccini P, Nuti A, Paoletti AM, Napolitano A, Melis GB, Bonuccelli U. Possible involvement of dopaminergic mechanism in the antimigraine action of flunarizine. Cephalalgia 1990;10:38
18. Maestri E, Manzoni GC, Marchesi G, et al. Effect of flunarizine on pituitary secretion by healthy men and in women with migraine. Eur J Clin Pharmacol 1987;32:525-7
19. Cerbo R, Formisano R, Falaschi P, Buzzi MG, Proietti A, Cusimano G, et al. Anterior pituitary hormone secretion during treatment with flunarizine in migrainous patients. Clin Neuropharmacol 1988;11:263-7
20. Cortelli P, Santucci M, Righetti F, et al. Neuroendocrinological evidence of an antidopaminergic effect of flunarizine. Acta Neurol Scand 1988;77:289-92
21. Cupini LM, Calabresi P, Silvestrini M, Troisi E, Matteis M, Argiro' G, et al. Prolactin response to bromocriptine in flunarizine treated migrainous women. Clin Neuropharmacol 1997;3:234-8
22. Nappi G, Savoldi F, Bono G, Martignoni E. Reserpine headache and prolactin release in migraine. Headache 1979;19:273-7
23. Murialdo G, Martignoni E, De Maria A, Bonura ML, Sances G, Polleri A. Changes in the dopaminergic control of prolactin secretion and in ovarian steroids in migraine. Cephalalgia 1986;6:43-9
24. Calabresi P, Silvestrini M, Stratta F, Cupini LM, Argiro' G, Atzei GP, et al. L-Deprenyl test in migraine: A neuroendocrinological study. Cephalalgia 1993;13:406-9
25. Nattero G, Corno M, Savi L, Isaia GC, Priolo C, Mussetta M. Prolactin and migraine: Effect of L-Dopa on plasma prolactin levels in migraineurs and normals. Headache 1986;26:9-12
26. Peroutka JS, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 1997;49:201-6
27. Peroutka SJ. Drugs effective in the therapy of migraine. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill 1996;21:487-502
28. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988;8:10-73
29. Ascoli M, Segaloff D. Adenohypophyseal hormones and their hypothalamic releasing factors. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1996;55:1363-82
30. Nappi G, Martignoni E, Bono G, Savoldi F, Murialdo G, Polleri A. THDA system function in migraine. In: Clifford Rose F, Zikha KJ, editors. Progress in Migraine Research. London: Pitman, 1981;1:110-23
31. Cangi F, Fanciullacci M, Pietrini U, Boccuni M, Sicuteri F. Emergence of pain and extrapain phenomena from dopaminimimetics in migraine. In: Pfaffenrath V, Lundberg PO, Sjaastad O, editors. Updating Headache. Berlin: Springer-Verlag, 1985:181-3
32. Sicuteri F, Boccuni M, Fanciullacci M, D'Egidio P, Bonciani M. A new nonvascular interpretation of syncopal migraine. In: Critchley MD, Friedman AP, Gorini S, Sicuteri F, editors. Advances in Neurology, vol 33, New York: Raven Press, 1982:199-200
33. Micheli FE, Fernandez Pardal MM, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord, 1989;4:139-46
34. Veerlspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia 1996;16:328-36